Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (161-170 of 442) with videos related to

Pageof 45
Sort By:
Journal of Managed Care & Specialty Pharmacy|July 24, 2025
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patternsJoseph F Merola, Sarah Welby, Helena Roque, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) QuestionnaireJeffrey M Cohen, Kareem Halim, Cara J Joyce, et al.
Journal of the American Academy of Dermatology|May 11, 2020
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trialJoseph F Merola, Robert Sidbury, Andreas Wollenberg, et al.
The American Journal of Managed Care|November 14, 2022
Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative reviewJoseph F Merola, April W Armstrong, Sharon Phares, et al.
The British Journal of Dermatology|January 30, 2019
Plasma levels of tumour necrosis factor-α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasisC M Johnson, K Fitch, J F Merola, et al.
The Journal of Rheumatology|May 3, 2017
Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual MeetingKristina Callis Duffin, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritisYinzhu Jin, Sarah K Chen, Hemin Lee, et al.
The Journal of Rheumatology|July 7, 2023
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?Rosario Agüero, Michael J Woodbury, Kathryn Lee, et al.
Current Rheumatology Reports|October 28, 2018
Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined ClinicsRebecca Haberman, Lourdes M Perez-Chada, Joseph F Merola, et al.
Rheumatology and Therapy|January 6, 2019
Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient SurveyJoseph F Merola, David Shrom, Jennifer Eaton, et al.
Pageof 45

Showing results (161-170 of 442) with videos related to

Sort By:
Pageof 45
Journal of Managed Care & Specialty Pharmacy|July 24, 2025
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patternsJoseph F Merola, Sarah Welby, Helena Roque, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) QuestionnaireJeffrey M Cohen, Kareem Halim, Cara J Joyce, et al.
Journal of the American Academy of Dermatology|May 11, 2020
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trialJoseph F Merola, Robert Sidbury, Andreas Wollenberg, et al.
The American Journal of Managed Care|November 14, 2022
Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative reviewJoseph F Merola, April W Armstrong, Sharon Phares, et al.
The British Journal of Dermatology|January 30, 2019
Plasma levels of tumour necrosis factor-α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasisC M Johnson, K Fitch, J F Merola, et al.
The Journal of Rheumatology|May 3, 2017
Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual MeetingKristina Callis Duffin, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritisYinzhu Jin, Sarah K Chen, Hemin Lee, et al.
The Journal of Rheumatology|July 7, 2023
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?Rosario Agüero, Michael J Woodbury, Kathryn Lee, et al.
Current Rheumatology Reports|October 28, 2018
Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined ClinicsRebecca Haberman, Lourdes M Perez-Chada, Joseph F Merola, et al.
Rheumatology and Therapy|January 6, 2019
Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient SurveyJoseph F Merola, David Shrom, Jennifer Eaton, et al.
Pageof 45